Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CA3
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Unknown
01
Overview
CA3 is a **novel small molecule inhibitor** targeting the YAP1 signaling pathway, specifically inhibiting YAP (Yes-associated protein 1) and TAZ (transcriptional co-activator with PDZ-binding motif). It disrupts YAP1/TAZ/TEAD signaling, induces apoptosis, reduces tumor cell invasion, migration, and spheroid formation, and suppresses epithelial-mesenchymal transition genes like Slug and Snail. Preclinical evidence supports its **anti-cancer activity** against mesothelioma and hepatocellular carcinoma, both as monotherapy and in combination with sorafenib. The compound is primarily studied in cell culture, spheroid, and xenograft models[2][3].
- Other names
- CA3CA-3CA 3
02
Targets
YAP1 (YES-associated protein–transcriptional enhancer factor domain complex)
Beyond the preview
Go deeper on CA3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CA3.